-
BHQ: A SERCA Lens on Calcium-to-Mobility Biology
2026-09-21
2,5-di-tert-butylbenzene-1,4-diol (BHQ) is more than a calcium-store perturbant: it is a mechanistic tool for connecting SERCA inhibition, ER stress, calcium signaling, and hematopoietic stem cell mobilization. This thought-leadership analysis translates recent HSC evidence into practical experimental strategy while defining the limits of cross-domain interpretation.
-
Gepotidacin’s Distinct Gyrase Cleavage Mechanism
2026-09-21
Gibson and colleagues show that gepotidacin inhibits Staphylococcus aureus gyrase through a cleavage profile dominated by single-stranded DNA breaks, unlike the double-stranded breaks typically associated with fluoroquinolones. Biochemical competition experiments and crystal structures connect this unusual activity to a distinct binding arrangement, providing a mechanistic framework for developing antibiotics active against fluoroquinolone-resistant bacteria.
-
Antipyrine as a Translational BBB Reference
2026-09-20
Antipyrine can serve as more than a familiar analgesic and antipyretic agent. When paired with qualified barrier models, bidirectional transport measurements, recovery analysis, and careful formulation control, it becomes a practical reference for translational pharmacology, pharmacokinetic studies, and drug metabolism research.
-
Temporal Transcriptomics for Host-Directed Anti-EBOV
2026-09-19
This preprint combines time-series transcriptomics, network analysis, causal inference, host-factor silencing, and drug screening to resolve how Ebola virus reshapes host cells over the course of infection. The study identifies condition-specific regulatory modules and reports Sorafenib and thioguanine as pharmacological inhibitors of EBOV replication, while also highlighting the need for further mechanistic and translational validation.
-
Candida krusei Forms Distinct BMEC Apoptosis Pathways
2026-09-19
Miao et al. show that the yeast and hypha phases of Candida krusei both trigger apoptosis in bovine mammary epithelial cells, but engage different dominant signaling routes. The yeast form primarily disrupts mitochondrial integrity, whereas the hypha form is more closely associated with death ligand/receptor signaling, with TLR2/ERK and JNK/ERK pathways contributing to the response.
-
EdU Flow Cytometry Assay Kits for S-Phase Studies
2026-09-18
EdU Flow Cytometry Assay Kits (Cy3) provide a practical route to quantify active DNA synthesis while preserving compatibility with cell-cycle dyes and immune-marker panels. This article translates a glioma immunology study into assay-ready workflows for proliferation, genotoxicity testing, pharmacodynamic studies, and immune-cell co-cultures.
-
Zosuquidar (LY335979): A Translational MDR Strategy
2026-09-17
Zosuquidar (LY335979) 3HCl offers translational researchers a selective way to interrogate P-glycoprotein-driven chemotherapy resistance. This thought-leadership article connects transporter biology, functional assay design, pharmacokinetic variability, and oncology development strategy while using recent transporter findings in MASH models to clarify both the promise and the limits of cross-disease translation.
-
Vorinostat and HO-1: A Dual-Readout Assay Strategy
2026-09-17
Explore how Vorinostat and suberoylanilide hydroxamic acid can pair epigenetic perturbation with real-time HO-1 activity measurements. This assay framework helps distinguish chromatin-driven growth arrest, mitochondrial apoptosis, and enzyme-level regulation in cancer biology research.
-
SAR131675: VEGFR-3 Inhibitor Workflows
2026-09-16
SAR131675 is a selective VEGFR-3 inhibitor for separating VEGFC-driven lymphatic, endothelial, and macrophage responses in cellular and disease-model workflows. This guide translates its nanomolar activity into practical assay designs while emphasizing formulation control, orthogonal validation, and the compound’s discontinued development status.
-
Tamoxifen Workflows for CreER and Cancer Research
2026-09-16
Tamoxifen enables time-controlled CreER-mediated gene knockout while also supporting estrogen-receptor and cancer-biology assays. This practical guide combines formulation, induction, assay controls, and developmental-safety safeguards to help distinguish intended recombination from compound-driven biology.
-
Berberine hydrochloride: Gut–Bone Research Workflows
2026-09-15
Translate berberine hydrochloride biology into reproducible workflows spanning AMPK, microbiome, tuft-cell, and osteoimmune assays. This practical guide emphasizes exposure control, matched controls, and troubleshooting for metabolic and gut–bone research rather than unsupported clinical claims.
-
RNA m6A in Plant–Virus Antagonism
2026-09-15
The reference study identifies RNA m6A modification as a dynamic battleground between plants and Cucumber mosaic virus (CMV). It shows that plant methyltransferases mark viral RNA for ECT8-dependent destabilization, while the CMV 2b protein disrupts the methyltransferase machinery and alters host m6A regulation.
-
M344 in Neuroblastoma: From Chromatin to Phenotype
2026-09-14
M344 is a cell-permeable histone deacetylase inhibitor whose value extends beyond a single potency number. This article connects chromatin remodeling with neuroblastoma phenotypes and proposes an evidence-led assay strategy for interpreting cytostasis, apoptosis, differentiation, and combination responses.
-
Wnt agonist 1 for Wnt Signaling Assays
2026-09-14
Wnt agonist 1 (BML-284) provides a controllable chemical entry point for β-catenin/TCF pathway studies, from reporter assays and differentiation models to mechanistic cancer research. This workflow connects pathway activation with the Wnt/NR2F2/GPX4 chemoresistance hypothesis while emphasizing controls, dose design, and interpretation limits.
-
NAD+ and AMPK: Rethinking Energy-Stress Assays
2026-09-13
A translational framework for using Nicotinamide Adenine Dinucleotide (NAD+) to distinguish redox chemistry, enzymatic activity, and autophagy signaling in energy-stress research. By integrating recent AMPK–ULK1 findings, this article shows why NAD+ measurements should support—not substitute for—mechanistic pathway validation.